Quick Answer
ZyVersa Therapeutics, Inc. reported Stockholders Equity of -$12.39 million for the year ending 2025.
- ZyVersa Therapeutics, Inc. showed a decrease of -245.4% in Stockholders Equity from 2024 to 2025.
- This data is from ZyVersa Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 31, 2026.
- XBRL data for this metric is available from 2021 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2021: -$439.00 | Q2 2021: -$1.2 thousand | Q3 2021: -$1.4 thousand | Q4 2021: -$2.26 million | Q1 2022: -$2.98 million | Q2 2022: -$3.37 million | Q3 2022: -$4.16 million | Q1 2023: $97.10 million | Q2 2023: $20.06 million | Q3 2023: $19.70 million | Q1 2024: $11.22 million | Q2 2024: $8.62 million | Q3 2024: $7.03 million | Q1 2025: $8.13 million | Q2 2025: $6.10 million | Q3 2025: -$11.73 million.
- Over the full 6 years of available data (2021 to 2025), ZyVersa Therapeutics, Inc.'s Stockholders Equity has declined by 448.5%.
- Historical annual values: Fiscal year 2025: -$12.39 million | Fiscal year 2024: $8.52 million | Fiscal year 2023: $11.07 million | Fiscal year 2022: $99.66 million | Fiscal year 2022: $99.68 million | Fiscal year 2021: -$2.26 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: